Lumenis Be. Ltd., a leading energy-based medical device company for aesthetic and eye care solutions, is proud to announce the launch of its breakthrough laser system designed to combat hair loss. Recently cleared by the Food and Drug Administration (FDA), FoLix becomes the first and only fractional laser choice for safe, effective, and natural hair loss treatment for women and men in the United States[1].
Affecting more than 85% of men and 50% of women[2], hair loss remains a persistent, widespread challenge. FoLix’s groundbreaking approach utilizes fractional laser and Lumenis’ proprietary technology tailored for hair. This is a revolution for hair loss patients, offering results in 4-6 monthly sessions with no chemicals, needles, anesthesia, surgery, or downtime.
FoLix’s unique technology delivers precise pulses of laser that leverage the body’s natural processes to stimulate hair follicles. Lumenis’ pre-clinical and clinical studies measuring the laser’s effect showed a positive impact on hair growth, with noticeable improvements in scalp hair appearance and an increase in hair count[3]. “Fractional lasers have been shown to have remarkable effects on the skin and now, finally, Lumenis has been able to harness that power and bring an innovative solution for hair stimulation,” said Dr. Marc Avram, a renowned hair transplant specialist and Clinical Professor of Dermatology at Weill Cornell Medical College (WCMC).
“With hair loss becoming a growing concern, FoLix emerges as a pivotal innovation for both patients and providers,” adds Dr. Neil Sadick, a world-leading dermatologist and researcher, and Clinical Professor of Dermatology at WCMC. “FoLix offers a unique opportunity to help those suffering from hair loss through short monthly sessions and with minimal discomfort and no downtime.”
“At Lumenis, we’re committed to transforming lives through science and innovation. FoLix is about more than just hair; it’s about having the self-confidence to live life to the fullest,” said Lumenis CEO Tzipi Ozer-Armon. “We are eager to collaborate with providers across the US to extend the influence and accessibility of this groundbreaking solution.”
